Securities Antitrust Consumer Fraud Structured Finance Whistleblower/Qui Tam Corporate Governance Mergers & Acquisitions ERISA Healthcare Fraud
PartnersOf Counsel Associates Staff Attorneys All
M & A Investigations New Federal Securities Cases Current CasesSettlements & Class Notices Accolades
Our Institutional Monitoring Service Our ProcessReporting Custom Monitoring
Articles Press Releases Television
Contact Us Join a Class Action Report a Fraud

New Federal Securities Cases

Dr. Reddy's Laboratories Ltd.

A class action lawsuit has been filed in the United States District Court for the District of New Jersey against Dr. Reddy's Laboratories Ltd. (NYSE:RDY)("Dr. Reddy's" or the "Company") on behalf of all persons and entities who acquired Dr. Reddy's securities during the period from June 17, 2015 through August 10, 2017 (the "Class Period"). The lawsuit seeks to recover damages for Dr. Reddy's investors under the federal securities laws.

The lawsuit alleges that the "company made materially false and or misleading statements or omissions" in connection with its corporate quality system.

On November 6, 2015, the Company received a warning letter from the FDA claiming that certain of its manufacturing facilities in India did not have proper controls over pharmaceutical production or records storage. On this news, the stock price fell from $64.41 to $52.81 per share. Then, on August 10, 2017, the Regulatory Authority of Germany stripped one of the Company's German plants of its Good Manufacturing Practices compliance certificate for similar reasons. On this news, the price fell from $32.30 to $30.33 per share, further damaging investors.

If you acquired Dr. Reddy's securities during the Class Period, you may, no later than October 24, 2017, request the court to appoint you lead plaintiff of the class. Although your ability to share in any recovery is not affected by the decision whether or not to seek appointment as a lead plaintiff, lead plaintiffs make important decisions that could affect the overall recovery for class members, including decisions concerning settlement.

If you are a current or former Dr. Reddy's shareholder and wish to obtain additional information, please fill out the contact form at the link below.

Investigation Contact Form

Dr. Reddy's Laboratories, Inc. Contact Form


Ira M. Press
Ira M. Press

Kirby McInerney LLP | 825 Third Avenue | NYC 10022 | Tel. 212.371.6600 | Fax 212.751.2540

Attorney Advertising - Prior Results do not Guarantee a Similar Outcome

Law Firm Web Design by Business Edge